Proteinuria Remission in Recurrent FSGS after Autologous Stem Cell Transplantation
- 26 December 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (5) , 736-738
Abstract
An abstract is unavailable. This article is available as a PDF only.Keywords
This publication has 9 references indexed in Scilit:
- Autoantibodies Targeting Nephrin in PodocytopathiesNew England Journal of Medicine, 2024
- High-dose chemotherapy and autologous hematopoietic stem cell transplantation for progressive systemic sclerosis: a retrospective study of outcome and prognostic factorsJournal of Cancer Research and Clinical Oncology, 2024
- Stem cell-based therapy for systemic lupus erythematousJournal of Translational Autoimmunity, 2024
- Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trialThe Lancet Gastroenterology & Hepatology, 2024
- Post-transplant recurrence of focal segmental glomerular sclerosis: consensus statementsKidney International, 2023
- A Systematic Review and Meta-Analysis of the Rate and Risk Factors for Post-transplant Disease Recurrence in Children With Steroid Resistant Nephrotic SyndromeKidney International Reports, 2022
- Sequential Stem Cell–Kidney Transplantation in Schimke Immuno-osseous DysplasiaNew England Journal of Medicine, 2022
- Recurrence of FSGS after Kidney Transplantation in AdultsClinical Journal of the American Society of Nephrology, 2020
- BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factorsBone Marrow Transplantation, 1997